Two Roswell Park Cancer Institute spinoff companies are moving their 15 employees into office and laboratory space in the Thomas R. Beecher Jr. Innovation Center.

The discovery-stage biotechnology companies – OncoTartis, which seeks anti-cancer drugs, and Tartis Aging, which seeks anti-aging drugs – will move into 5,700 square feet of wet lab and office space on the fourth floor of the Innovation Center on the Buffalo Niagara Medical Campus.

The companies’ technologies are licensed from the labs of Andrei V. Gudkov, who moved his first company, Cleveland BioLabs, from the Cleveland Clinic to Buffalo in 2007.

“OncoTartis and Tartis Aging are perfect examples of what we need to see more of here in Buffalo,” Patrick J. Whalen, chief operating officer of the Medical Campus, said in a statement Monday. “Dr. Gudkov and Cleveland BioLabs moved to the BNMC several years ago to better collaborate with Roswell Park Cancer Institute. And thanks to the groundbreaking research at Roswell Park, they continue to grow and spin off companies, creating more jobs and economic-development opportunities in Buffalo as they evolve.”

Gudkov has served as senior vice president of basic science at Roswell Park and as chief scientist of Cleveland BioLabs, which is best known for its continuing development of a drug to combat radiation sickness.

Cleveland BioLabs has shared lab space at 73 High St. with OncoTartis and Tartis Aging. The two Tartis companies are moving to the Innovation Center because they have outgrown their space on High Street but wanted to stay on the Medical Campus.

“We are very happy to find space in the Innovation Center, which allows us to expand our research and at the same time continue to be close to our colleagues at CBLI and Roswell Park,” Aleksandra Kotlyarova, director of operations for the Tartis companies, said in the statement.